Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

Selank vs Semax

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

Selank: DSemax: D
AttributeSelankSemax
CategoryNootropic / AnxiolyticNootropic / Neuroprotective
Evidence RatingD — PreclinicalD — Preclinical
Clinical StatusApproved in Russia as an anxiolytic nasal spray; not approved elsewhereApproved in Russia and Ukraine for stroke and cognitive disorders; not approved elsewhere
MechanismSelank (C33H57N11O9, half-life ~2-10 minutes) crosses the blood-brain barrier. It acts as a positive allosteric modulator of GABA-A receptors, increasing GABA binding affinity without directly activating the receptor (similar to benzodiazepines but without sedation or dependence). It enhances monoam...Semax is a brain-selective heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MW ~813.88 g/mol) that crosses the blood-brain barrier via intranasal absorption. It increases brain-derived neurotrophic factor (BDNF) expression and upregulates trkB receptors, supporting neuroplasticity and long-term memory for...
Half-Life~3–5 minutes (parent compound); active metabolites persist longer~3–5 minutes; intranasal extends effective duration
Bioavailability——
Molecular Weight~751.9 g/mol~813.9 g/mol
WADA StatusNot ListedNot Listed
Research Half-Life~3–5 minutes (parent compound); active metabolites persist longer~3–5 minutes; intranasal extends effective duration
Key Use Cases
  • Cognitive Enhancement
  • Cognitive Enhancement
Safety Concerns
  • Safety is excellent with minimal adverse effects in published studies
  • A peer-reviewed study stated Selank had desirable effects of low-dose benzodiazepines with none of the side effects
  • No dependence potential, no withdrawal effects -- unlike benzodiazepines
  • Generally favorable safety profile with uncommon mild side effects and no dependence potential
  • No significant hormonal effects despite ACTH-fragment origin — brain-selective mechanism reduces systemic side effects
  • Administered intranasally — mild nasal irritation possible; proper spray technique recommended
Contraindications
  • Pregnancy and breastfeeding (insufficient data)
  • Hypersensitivity to selank or its components
  • Concurrent use with MAOI inhibitors without medical supervision
  • Pregnancy and breastfeeding (insufficient data)
  • Acute psychosis (theoretical concern regarding dopaminergic enhancement)
  • Individuals with mood disorders should use caution (dopamine effects may interact with mood conditions in complex ways)
  • Combining with other dopamine-active substances warrants caution
Regulatory (US)Not FDA-approved. Research chemical only.Not FDA-approved. Removed from FDA Category 2 on April 15, 2026. PCAC review scheduled July 23-24, 2026. Previously classified as Category 2, prohibiting compounding. Research chemical.

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All ComparisonsBrowse Catalog

Your Cart

Your cart is empty

Browse our catalog to add research compounds.